Project Grant F31HL179993
- Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Ohio State University a Project Grant of $1.1M under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the molecular mechanisms of immune suppression in Acute Respiratory Distress Syndrome (ARDS). The award, issued July 1, 2026, with an ultimate completion date of June 30, 2033, funds research focused on discovering and characterizing F-box proteins—immunosuppressive molecules that degrade...
- This Project Grant, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports mechanistic research investigating the role of Toll-Like Receptor-9 (TLR9) in lung structural cells during influenza and methicillin-resistant Staphylococcus aureus (MRSA) coinfection. The $100,228 award, issued December 1, 2026, and concluding April 30, 2029, funds research conducted at the University of Michigan to identify how TLR9...
- This Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research investigating the protective mechanisms of bone marrow-derived mesenchymal stromal cells (BMSCs) against acute lung injury (ALI). The award of $761,261.27 to The Trustees of Columbia University in the City of New York, Health Sciences Division, is effective September 1, 2025, through November 15, 2025. The research will employ live...
- This $731,287 Project Grant, awarded July 1, 2026, by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research into the mechanisms driving chronic lung allograft dysfunction (CLAD) following lung transplantation. The University of California, San Francisco will conduct mechanistic and translational research investigating how mammalian target of rapamycin (mTOR) signaling drives airway epithelial cell reprogramming...
- This Project Grant award of $174,744 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) funds research on the role of the phosphatase SHP1 (Src Homology region 2 Domain-containing Phosphatase-1) in modulating acute lung injury. The research will be conducted at the University of California, San Francisco from June 2, 2026 through May 31, 2031. The project delivers mechanistic research products through two primary...
- Federal Project Grant Award Summary Baylor College of Medicine received a $508,290 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 1, 2026, through March 31, 2030. The award funds mechanistic research investigating the role of BHLHE40 in orchestrating mucosal CD8 T cell responses in sarcoidosis lungs. The research addresses critical knowledge gaps in sarcoidosis pathogenesis by examining CD8...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the Regents of the University of Michigan a Project Grant of $100,228.00 under the Cardiovascular Diseases Research program (CFDA 93.837) to support research investigating mechanisms for induction of antibacterial lung-resident CD4+ T cells. The award, effective December 1, 2026, through April 19, 2029, funds basic immunological research aimed at understanding how Streptococcus pneumoniae (SPN) infection...
- This Project Grant, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), funds basic immunological research investigating the mechanisms of neointimal lesion formation in pulmonary hypertension (PH). The Leland Stanford Junior University will conduct hypothesis-driven mechanistic studies examining how T cell populations—specifically pathogenic CD4+ helper T cells and regulatory T cells—contribute to abnormal vascular...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Washington University a Project Grant of $233,250 on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the mechanisms by which mycophenolic acid (MPA) influences neutrophil development and effector function. This research addresses a significant clinical problem: over 80 percent of lung transplant recipients receive MPA as immunosuppressive therapy...
- This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports fundamental immunological research at the University of Toledo Health Science Campus Division. The award of $162,000 obligated on September 1, 2025, with completion targeted for August 31, 2027, funds research to elucidate the cardioprotective role of fetal-derived CD8+ T cells during viral-induced myocarditis....
DISSECTING LUNG ALVEOLAR MACROPHAGE INTERACTIONS WITH T CELLS - SUMMARY BALANCED HOST INFLAMMATION DURING PULMONARY INFECTIONS IS REQUIRED TO PREVENT TISSUE DAMAGE DURING ACUTE LUNG INJURY (ALI). T CELL-DEPENDENT INFLAMMATION IS LINKED TO BINDING THE CO-STIMULATORY MOLECULES CD80 AND CD86 ON LUNG ALVEOLAR MACROPHAGES (AMS) WHICH DRIVES BOTH T CELL ACTIVATION (VIA CD28 LIGATION) AND INHIBITION (VIA CTLA4 LIGATION). WHILE AMS ARE NORMALLY POOR ACTIVATORS OF NAIVE T CELLS, DYSREGULATION OF T CELL MODULATORY MOLECULES, CAN ALTER T CELL-DEPENDENT RESOLUTION AND PULMONARY DAMAGE DURING ALI, INFECTION, OR ASTHMA. HOWEVER, DUE TO EXPERIMENTAL CHALLENGES, WE LACK A MECHANISTIC UNDERSTANDING OF SHARED AND UNIQUE PATHWAYS REGULATING CD80 AND CD86 IN AMS PROHIBITING DEVELOPMENT OF THERAPEUTICS TO TARGET THESE KEY INTERACTIONS. USING A NEW EX VIVO MODEL OF AMS CALLED FETAL LIVER-DERIVED ALVEOLAR-LIKE MACROPHAGES (FLAMS), I AM OVERCOMING THIS EXPERIMENTAL BARRIER TO DEFINE NEW MECHANISMS REGULATING AM FUNCTION. MY PRELIMINARY DATA SHOW THAT RESTING FLAMS AND FLAMS ACTIVATED WITH THE PROINFLAMMATORY CYTOKINE IFNG, DO NOT ROBUSTLY EXPRESS EITHER CD80 OR CD86, LIMITING T CELL INTERACTIONS. HOWEVER, BLOCKING THE METABOLISM-RELATED KINASES GLYCOGEN SYNTHASE KINASE 3A AND 3B (GSK3A/B), THAT MODULATE IFNG RESPONSES, DRIVES HIGH CD80 AND CD86 EXPRESSION IN ACTIVATED FLAMS, RESULTING IN ROBUST T CELL INTERACTIONS. USING TRANSCRIPTOMICS AND TARGETED KNOCKOUTS IN FLAMS, I FOUND THAT THE UPREGULATION OF CD80 AND CD86 ARE UNIQUELY CONTROLLED. CD86, BUT NOT CD80 EXPRESSION, REQUIRED THE PRODUCTION AND SIGNALING OF INTERFERON BETA 1 (IFNB). TO INVESTIGATE CD80 EXPRESSION I FOUND NEW CANDIDATE REGULATORS USING A GENOME-WIDE FORWARD GENETIC SCREEN IN ACTIVATED FLAMS BLOCKED FOR GSK3A/B. TOGETHER MY PRELIMINARY DATA HIGHLIGHT OUR CONTINUED LACK OF UNDERSTANDING OF CD80 AND CD86 REGULATION AND DEFINE NEW LINKS BETWEEN AMS, METABOLISM, AND T CELL EFFECTOR FUNCTION, AND ALI PROGRESSION. MY OVERALL HYPOTHESIS IS THAT THE DISTINCT REGULATION OF CD80 OR CD86 ON AMS WILL PREVENT DYSREGULATED PULMONARY T CELL RESPONSES TO PROTECT AGAINST SEVERE ALI. THE GOAL OF THIS PROPOSAL IS TO USE GENETIC AND CHEMICAL APPROACHES IN FLAMS TO DISSECT SHARED AND UNIQUE MECHANISMS REGULATING CD80 AND CD86 EXPRESSION AND DETERMINE THEIR CONTRIBUTION TO T CELL FUNCTION IN THE LUNGS. IN AIM 1, I WILL DETERMINE THE MECHANISMS UNIQUELY REGULATING CD80 AND CD86 IN AMS. IN AIM 2, I WILL EXAMINE HOW DYSREGULATION OF CD80 AND CD86 IN AMS ALTERS T CELL FUNCTION AND ALI SEVERITY. TOGETHER, THESE AIMS WILL DEFINE THE REGULATORY MECHANISMS OF CD80 AND CD86 AND DISSECT THEIR CONTRIBUTION TO T CELL FUNCTION IN THE LUNGS. A BETTER UNDERSTANDING OF HOW APC-DEPENDENT LIGANDS CD80 AND CD86 ARE REGULATED, WILL IDENTIFY NEW STRATEGIES TO MODULATE T CELL FUNCTION AND PROTECT FROM ACUTE LUNG INJURY. THE EXPERIMENTS IN THIS PROPOSAL WILL BE PERFORMED IN THE SUPPORTIVE TRAINING ENVIRONMENT AT MICHIGAN STATE UNIVERSITY AND DEPARTMENT OF MICROBIOLOGY, GENETICS, AND IMMUNOLOGY. MY FULL TRAINING PLAN WILL HELP ME DEVELOP THE RESEARCH AND COMMUNICATION SKILLS NECESSARY TO BECOME A SUCCESSFUL INDEPENDENT RESEARCHER.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $44.2k | 4/7/26 |